Prospective Liver Study

Prospective Analysis of Liver Cancer Treatment and Interventions

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01539993

Enrollment

400

Registered

2012-02-28

Start date

2008-11-30

Completion date

2014-01-31

Last updated

2014-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Keywords

Hepatocellular carcinoma, Liver metastases, Cholangiocarcinoma, Percutaneous treatments, RFA, TACE, DEB

Brief summary

This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.

Exclusion criteria

* Severe liver disfunction * Active uncontrolled infection * Significant underlying medical of physical illness

Design outcomes

Primary

Measure	Time frame	Description
Assess efficacy of percutaneous and transarterial treatments for liver cancer.	1 month	QOL questionnaire will be collected during follow up visit.

Secondary

Measure	Time frame	Description
long term follow up	3 months, 6 months 1year	Patients will be administered QOL during 3 months, 6 months and 1 year follow up.

Countries

United States

Outcome results